S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Having Trouble in Your Trading? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Having Trouble in Your Trading? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Having Trouble in Your Trading? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Having Trouble in Your Trading? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price & News

$11.55
0.00 (0.00%)
(As of 05/31/2023 ET)
Compare
Today's Range
$11.40
$11.82
50-Day Range
$11.50
$18.08
52-Week Range
$6.15
$22.11
Volume
1.69 million shs
Average Volume
2.18 million shs
Market Capitalization
$1.23 billion
P/E Ratio
13.13
Dividend Yield
N/A
Price Target
$21.50

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
86.1% Upside
$21.50 Price Target
Short Interest
Healthy
9.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.25mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$3.97 M Sold Last Quarter
Proj. Earnings Growth
16.52%
From $1.15 to $1.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.90 out of 5 stars

Medical Sector

35th out of 1,006 stocks

Pharmaceutical Preparations Industry

14th out of 492 stocks


CPRX stock logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
Stop Trading Like A Turtle
Performing at your best requires quick reaction and adaptability. While slow and steady progress works for some, having a tool that enables informed trading decisions is essential amid volatility. It's 2023. Why trade like a turtle when you could track down new opportunities like a cheetah?
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading Down 17.3%
Catalyst Pharma (CPRX) Receives a Buy from H.C. Wainwright
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings
3/15/2023
Today
5/31/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
76
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$21.50
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$15.50
Forecasted Upside/Downside
+86.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$83.08 million
Pretax Margin
48.57%

Debt

Sales & Book Value

Annual Sales
$214.20 million
Cash Flow
$0.81 per share
Book Value
$3.15 per share

Miscellaneous

Free Float
91,120,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
1.11

Social Links


Key Executives

  • Patrick J. McEnanyPatrick J. McEnany
    Chairman, President & Chief Executive Officer
  • Steven R. MillerSteven R. Miller
    Chief Operating & Scientific Officer
  • Alicia GrandeAlicia Grande
    CFO, Treasurer, Principal Accounting Officer & VP
  • Gary IngenitoGary Ingenito
    Chief Medical & Regulatory Officer
  • Stanley Iyadurai
    Senior VP-Medical Affairs & Drug Discovery













CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2023?

4 equities research analysts have issued twelve-month target prices for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $25.00. On average, they predict the company's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2023?

Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX stock has decreased by 37.9% and is now trading at $11.55.
View the best growth stocks for 2023 here
.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 9,490,000 shares, a decline of 15.2% from the April 30th total of 11,190,000 shares. Based on an average daily volume of 1,920,000 shares, the short-interest ratio is presently 4.9 days. Currently, 9.6% of the company's shares are sold short.
View Catalyst Pharmaceuticals' Short Interest
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its earnings results on Wednesday, March, 15th. The biopharmaceutical company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.21 by $0.01. The biopharmaceutical company earned $60.76 million during the quarter, compared to the consensus estimate of $60.64 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 34.72% and a net margin of 38.76%.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $375.00 million-$385.00 million, compared to the consensus revenue estimate of $381.54 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.54%), State Street Corp (7.11%), Dimensional Fund Advisors LP (2.25%), Geode Capital Management LLC (1.75%), Two Sigma Advisers LP (1.49%) and Jupiter Asset Management Ltd. (1.35%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $11.55.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.23 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $0.88 on an earnings per share basis.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -